Navigating Your Toughest Price And Market Access Challenges

NAVLIN by EVERSANA is a single, integrated platform that combines data, software and insights to answer your most challenging price and access questions.

We help you plan and evaluate strategies to achieve success in U.S. and global markets.

Explore NAVLIN

Comprehensive. Intuitive. Integrated.

Comprehensive Ecosystem

NAVLIN by EVERSANA delivers a single easy-to-use platform that integrates highly accurate price and access data, software and insights to drive exponential value in the life sciences.

NAVLIN Price & Access Data

NAVLIN Price & Access Data is the industry’s most comprehensive, highly accurate database of global price and market access intelligence, providing the right answers to the right questions to inform your strategy at launch and beyond.

NAVLIN Price & Access Data

NAVLIN Price & Access Software

NAVLIN Price & Access Software provides the most accurate and comprehensive enterprise software solution to address global pricing challenges for pharmaceutical manufacturers.

NAVLIN Price & Access Software

NAVLIN Insights

NAVLIN Insights delivers the most innovative market research solutions for biopharmaceutical companies’ business questions from pipeline to loss of exclusivity.

NAVLIN Insights

NAVLIN Daily

NAVLIN Daily keeps you up to date and informed by connecting the dots on how the day’s biggest stories affect your business. Experience global price and market access news without all the noise.

NAVLIN Daily

NAVLIN Revenue Management

NAVLIN Revenue Management brings together all critical revenue management operations, along with the power of NAVLIN Price & Access Data, to deliver efficient, intuitive, accurate and compliant tracking and reporting – all in one innovative & integrated digital platform.

NAVLIN Revenue Management

What’s New

NAVLIN’s new release makes it easier to navigate the most complex pricing decisions. It provides enhancements across the full lifecycle and is optimized for early access and launch support.

The new AI assistant is now available across the platform and features natural language, AI-driven querying of the pricing database. Those who are software users will see enhancements to predictability models.

What’s New

Comprehensive Ecosystem

NAVLIN by EVERSANA delivers a single easy-to-use platform that integrates highly accurate price and access data, software and insights to drive exponential value in the life sciences.

NAVLIN Price & Access Data

NAVLIN Price & Access Data

NAVLIN Price & Access Data is the industry’s most comprehensive, highly accurate database of global price and market access intelligence, providing the right answers to the right questions to inform your strategy at launch and beyond.

NAVLIN Price & Access Software

NAVLIN Price & Access Software

NAVLIN Price & Access Software provides the most accurate and comprehensive enterprise software solution to address global pricing challenges for pharmaceutical manufacturers.

NAVLIN Insights

NAVLIN Insights

NAVLIN Insights delivers the most innovative market research solutions for biopharmaceutical companies’ business questions from pipeline to loss of exclusivity.

NAVLIN Daily

NAVLIN Daily

NAVLIN Daily keeps you up to date and informed by connecting the dots on how the day’s biggest stories affect your business. Experience global price and market access news without all the noise.

NAVLIN Revenue Management

NAVLIN Revenue Management

NAVLIN Revenue Management brings together all critical revenue management operations, along with the power of NAVLIN Price & Access Data, to deliver efficient, intuitive, accurate and compliant tracking and reporting – all in one innovative & integrated digital platform.

What’s New

What’s New

NAVLIN’s new release makes it easier to navigate the most complex pricing decisions. It provides enhancements across the full lifecycle and is optimized for early access and launch support.

The new AI assistant is now available across the platform and features natural language, AI-driven querying of the pricing database. Those who are software users will see enhancements to predictability models.

Experience the
NAVLIN difference

650+
Global sources monitored daily for price, HTA, policy and tender data
+99%
Accuracy of real-time reimbursement, HTA and tender data
<24
hours Speed of updates made from time of publication
4,000+
Medical and pharmacy decision-making executives included in NAVLIN Insights survey panels
24x7
Continuous operations and support
99.5%
Customer satisfaction with market research insights
Real quotes from real clients

Client Delight

This is an amazing tool. The data quality, insights, and user-friendliness are far superior to any other pricing database I’ve used in my career.

Enric Muñoz

Sr. Director, Global Strategic Pricing Head, Takeda

To say thank you seems so trivial. I really appreciate all the hard work and time that you all have invested.

Sr. Director, Global Strategic Pricing Head, Takeda

My team literally could not do what they do without this solution.

Sr. Director, Market Access

Intelligent, intuitive, insightful, helpful, and responsive!

US Payer & Channel Access, Pfizer

NAVLIN Daily News

Checkout Today’s News

Germany's Federal Council Rejects Confidential Drug…

The German Federal Council (Bundesrat) has rejected the proposal for confidential drug reimbursement amounts in the Medical Research Act (MFG). The Council essentially argues that the move would undermine transparency in health economics and entail high bureaucratic and financial costs, without bringing tangible benefitsHealth insurers like AOK and GKV-Spitzenverband welcomed the Council's decision, emphasizing that secret drug prices could drive up pharmaceutical costs by billions of euros and increase the burden for premium payers. They further argue that transparency enables doctors to prescribe more economicallyThe rejection from the Bundesrat over the weekend means confidential pricing in Germany is looking far less likely than before, as the G-BA also recently rejected the bill

U.S. Pharma and Biotech Summit: The Highs & Lows of…

At the Financial Times U.S. Pharma and Biotech Summit, panelists agreed that biotech innovation is strong and attractive to investors, but U.S. policy development brings an uncertain futureDarius Lakdawalla, Quintiles Chair in Pharmaceutical Development, USC has no doubt that U.S. legislation targeting Chinese biotech companies could increase the risk of drug shortages and disrupt the supply chainRegardless, growth potential is seen in many areas like cardiovascular and neurodegenerative conditions, while Amit Sinha, Chief Investment Officer, Goldman Sachs, proposed: “Every part of pharma that's not in obesity space needs to think about whether or not they can be in that space”

U.S. Pharma and Biotech Summit: The FTC's Antitrust…

At the Financial Times U.S. Pharma and Biotech Summit in New York, Rahul Rao, Deputy Director, Bureau of Competition, Federal Trade Commission (FTC), said about the pharma market, “What has happened is that we look around the market is something is a little bit off,” considering greater consolidation, higher prices, reduced access, and pain points throughout the economyRao described two types of remedies to misaligned incentives: Structural remedy involving divesture or walking the deal; and Behavioral remedy, or a promise or commitment to not do something, but he said, asking a company to refrain from doing something doesn’t remove the incentive for them to do it, so behavioral remedies often failAfter facilitating a public workshop in 2022 on new approaches to antitrust, the FTC is now developing a report on PBMs and how vertical integration and incentives influence pricing

U.S. Pharma and Biotech Summit: Solving the Drug…

At the Financial Times U.S. Pharma and Biotech Summit in New York, panelists discussed the multifaceted drug pricing landscape in America, where expenditure is rising without any additional benefit coming from the rise, observed Sarah Emond, President and CEO, Institute for Clinical and Economic Review (ICER)“In Washington, I don't think anybody is steering the ship,” concluded  John O'Brien, President and CEO, National Pharmaceutical Council, “I'm concerned that all of these cuts in the industry are going to hit an artery”— In other words, the official is worried that the sum total of U.S. policies could chase the industry away from the country which is currently the global leaderBoldly, Emond called on the audience, which included many industry players, to stop paying rebates and go public, and O’Brien said everyone should openly agree when drugs go generic

AbbVie Faces Lawsuit Over Alleged Humira Market Abuse…

The Pharmaceutical Accountability Foundation (PAF) is accusing AbbVie of abusing its market dominance to overcharge for its rheumatoid arthritis drug, Humira. PAF claims AbbVie overcharged to the tune of EUR 1.2 billion to the Dutch healthcare system by "excessively" pricing HumiraAbbVie made EUR 2.3 billion on Humira in the Netherlands from 2004 to 2018, indicating a 78% profit margin, whereas the company claims 25% as "fair" profit. According to PAF, AbbVie has also made a potential of $110 billion in excessive profits worldwide on Humira from 2003 to 2022While AbbVie argues that the Dutch court doesn't have jurisdiction over the case, PAF bases its case on unfair pricing, patent manipulation, and prioritizing profits over accessibility of essential medicines. The court's decision on whether to proceed with the case is expected by June 26

G-BA Rejects Confidential Drug Prices in Germany

The Federal Health Committee of Germany (G-BA) rejects the proposal for confidential drug reimbursement amounts within the draft Medical Research Act (MFG) - The Federal Council (Bundesrat) is set to discuss these proposals over the weekendThe group argues that confidentiality could increase bureaucracy and lack transparency without delivering real benefits. Instead, the G-BA wants to use the agreed reimbursement amount as the benchmark for setting fixed amounts, not the pharmaceutical company's initial market launch priceThe group also proposes establishing a central advisory center with the Institute for Quality and Efficiency in Health Care (IQWiG) to focus on evidence-based drug development and data generation. On top of this, the G-BA seeks to embed its role in clinical assessments and scientific advice on health tech at the European level

Sanders-Sponsored Report Claims Weight-Loss Drugs…

A new report published by Senator Bernie Sanders’ (I-VT) staff found that broad coverage of Novo Nordisk’s semaglutide products (Wegovy and Ozempic) at their current prices could “bankrupt” both federal health programs and the broader U.S. health care systemThe new report claims that even while taking into account estimated manufacturer discounts, broad coverage of weight-loss medications could cost $411 billion per year if just half of U.S. adults with obesity took Wegovy and other new weight-loss drugs, surpassing to amount Americans spent on all retail prescription drugs in 2022 ($406 billion) Ozempic, which is indicated for the treatment of type 2 diabetes, is sold at a list price of $969 per month in the U.S. Wegovy, which is prescribed for the treatment of obesity, is listed at $1,349 per month in the U.S. According to the report, Novo currently sells Wegovy in Denmark for a list price of $186. The medicine can be purchased for $137 in Germany and $92 in the UK

ICER Releases Revised Evidence Report on Lykos…

After the draft evidence report was open for public comment until April 22, 2024, the Institute for Clinical and Economic Review (ICER) issued a revised evidence report evaluating the comparative clinical effectiveness and value of Lykos Therapeutics' (formerly MAPS Public Benefit Corporation) 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy (MDMA-AP) for the treatment of post-traumatic stress disorder (PTSD)ICER's evaluation indicates that for the effects of MDMA, the trials were essentially unblinded, with nearly all patients who received MDMA correctly identifying that they were in the MDMA arm of the trials. Also, very strong prior beliefs of those involved in the trials (as investigators, therapists, and patients) about the benefits of MDMA-AP conclude that the current publicly available evidence for MDMA-AP is insufficient (“I”). Given this, the evidence is also insufficient (“I”) to compare MDMA-AP with trauma-focused psychotherapiesICER clarifies that the economic analyses of MDMA-AP in the revised evidence report are exploratory, offering insights into costs and benefits under the assumption of the accuracy of MAPP trial results. Due to its exploratory nature, ICER refrains from presenting threshold prices and health benefit price benchmarks

ISPOR 2024: Global Consequences of the IRA in the U.S.…

In response to the Inflation Reduction Act (IRA), Diana Brixner from the University of Utah, thinks companies will evolve R&D strategies: “Blockbuster drugs will be looked at differently,” she said at ISPOR 2024, adding that drug developers will make decisions on pipelines and investments according to negotiations by drug and not by indication; Likewise, in Europe, Brixner foresees many fallouts from direct price negotiation including decreased investment in drug innovationChristopher Teale from TealeHeath sees a plethora of issues with the JCA, like complex methodologies, unrealistic timelines, insufficient expertise, and disconnected price setting at the national level; According to Teale, the JCA only indirectly influences access, because access depends on national initiatives, which may be easier to implementChanges in both the U.S. and Europe create uncertainty for drug manufacturers, according to Sam Mettam from Jazz Pharmaceuticals, who recommends that players figure out how to minimize the impact of mistakes and maximize the amount of evidence generated per dollar

ISPOR 2024: The Motives Behind CMS Price Negotiation

At ISPOR 2024, Lou Garrison, PhD, Office of Health Economics, Seattle, WA, questioned the motives of the U.S. Centers for Medicare & Medicaid Services (CMS): “Most HTA processes talk about price at launch, not 10 years later like CMS, when there are 10 years of data…Maybe there is a hidden agenda to negotiate at launch, so this is to put the camel in the tent”Regarding potential discrimination in QALY, Garrison blames concerns on politics: “QALY technically could discriminate against life expectancy, but we have mathematical ways to adjust it to favor people with certain conditions. There's a workaround”The National Health Council (NHC) recently led a roundtable for patient community members to devise a way forward for developing patient input opportunities at the CMS which is now considering combination sessions for drugs that treat similar conditions, and live-streamed meetings

Connect With Our Team Of Global Experts

Contact Us

Feel free to get in touch with us via email, live chat, or schedule a meeting!